Rubraca Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations

Rubraca Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations
Rubraca (rucaparib), Clovis Oncology's PARP inhibitor, shrank tumors in 44% of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations included in a Phase 2 clinical trial, the company announced. The treatment, which already is approved for ovarian cancer, also reduced PSA levels — a biomarker of prostate cancer — in 51.1% of patients with BRCA mutations. The findings were presented recently at the European Society of Medical Oncology (ESMO) 2018 Congress by Wassim Abida, a medical oncologist at the Memorial Sloan Kettering Cancer Center, and principal investigator for the Phase 2 study. The poster was titled "Preliminary results from TRITON2: a phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations." Nearly 12% of men with mCRPC have a mutation in the BRCA1 or BRCA2 genes, which play key roles in repairing errors in the DNA. These tumors are more susceptible to further DNA damage, and often respond well to treatments that block other proteins involved in DNA damage repair. The PARP enzymes are at play when BRCA proteins are not functioning properly, and PARP inhibitors have shown great promise in breast and
Subscribe or to access all post and page content.